dataset
posted on 2023-04-03, 20:01 authored by Ana Galan-Cobo, Christine M. Stellrecht, Emrullah Yilmaz, Chao Yang, Yu Qian, Xiao Qu, Ishita Akhter, Mary L. Ayres, Youhong Fan, Pan Tong, Lixia Diao, Jie Ding, Uma Giri, Jayanthi Gudikote, Monique Nilsson, William G. Wierda, Jing Wang, Ferdinandos Skoulidis, John D. Minna, Varsha Gandhi, John V. Heymach Supplementary Data from Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado
Funding
University of Texas Southwestern Medical Center
University of Texas MD Anderson Cancer Center Lung UT
LKB1
CPRIT
Lung Cancer Moon Shot
Kyte Family
Jeff Hepper
Normal Godinho
Rexanna's Foundation for Fighting Lung Cancer
Weaver Foundation
CCSG
Stand Up To Cancer-American Cancer Society Lung Cancer Dream Team Translational Research Grant
Jane Ford Petrin donation
Helen H. Laughery donation
American Association for Cancer Research
SU2C
History
ARTICLE ABSTRACT
Loss-of-function somatic mutations of STK11, a tumor suppressor gene encoding LKB1 that contributes to the altered metabolic phenotype of cancer cells, is the second most common event in lung adenocarcinomas and often co-occurs with activating KRAS mutations. Tumor cells lacking LKB1 display an aggressive phenotype, with uncontrolled cell growth and higher energetic and redox stress due to its failure to balance ATP and NADPH levels in response to cellular stimulus. The identification of effective therapeutic regimens for patients with LKB1-deficient non–small cell lung cancer (NSCLC) remains a major clinical need. Here, we report that LKB1-deficient NSCLC tumor cells displayed reduced basal levels of ATP and to a lesser extent other nucleotides, and markedly enhanced sensitivity to 8-Cl-adenosine (8-Cl-Ado), an energy-depleting nucleoside analog. Treatment with 8-Cl-Ado depleted intracellular ATP levels, raised redox stress, and induced cell death leading to a compensatory suppression of mTOR signaling in LKB1-intact, but not LKB1-deficient, cells. Proteomic analysis revealed that the MAPK/MEK/ERK and PI3K/AKT pathways were activated in response to 8-Cl-Ado treatment and targeting these pathways enhanced the antitumor efficacy of 8-Cl-Ado.
Together, our findings demonstrate that LKB1-deficient tumor cells are selectively sensitive to 8-Cl-Ado and suggest that therapeutic approaches targeting vulnerable energy stores combined with signaling pathway inhibitors merit further investigation for this patient population.
